Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
May 21, 2021 pulse
0
0 Likes
0000
More by pulse

Related Articles

Uncategorized
Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
- by pulse
Uncategorized
Example of press release
Example of press release
- by pulse
Ferring Pharmaceuticals announces changes to Board of Directors
- by pulse

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.

OK

Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.

OK

Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals

OK

Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.

OK

Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.

OK

Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.

OK